This adds to the €4.7 million the company raised in May of this year.
The startup develops R-One, which assists in cardiovascular operations such as inserting stents into arteries. It claims its technology allows for greater precision.
Robocath plans to market the robotics platform in Europe and the Middle East next year.
The new funds will also be invested in developing new solutions.
“Supernova Invest’s commitment to us, by investing through the CAIT fund, demonstrates the potential of our technology and its many advantages," said Philippe Bencteux, president of Robocath.
"R-One opens up new and exciting possibilities for remote interventions, which will help to significantly improve patient care during vascular emergencies. Soon, surgeons will be able to operate whilst taking up a position several meters away from the patient and, in the future, this will increase to several hundred kilometers, with the surgeon working from an expert center," he said.
"These remote interventions will improve the management of pathologies such as heart attacks and strokes, where time is key to survival. I am certain that this technology will allow us to meet the major challenges of tomorrow’s medicine."